Topiramate reduces basal anxiety and relieves ethanol withdrawal-induced anxious behaviors in male rats.

Abstract

Anxiety disorders are associated with increased impairments in psychosocial functioning, work productivity and health-related quality of life. In addition, anxiety is a common symptom of ethanol withdrawal and it strongly contributes to relapse. Benzodiazepines are frequently prescribed for relief of anxiety and ethanol withdrawal symptoms but considerable side effects, such sedation, tolerance and dependence, are observed during treatment. Therefore, better drugs are needed for the treatment of anxiety states. The purpose of this study was to investigate whether topiramate would reduce basal levels of anxiety and ethanol-withdrawn induced anxiety in male rats; the elevated plus maze (EPM) was used as an animal model of anxiety. In Experiment 1, topiramate (0, 10, and 40 mg/kg, i.g.) and diazepam (1 mg/kg, i.p.) was acutely and repeatedly administered to naive rats. In Experiments 2 and 3, topiramate (0 or 40 mg/kg, i.g.) was acutely and chronically administered in early (72 hr after ethanol removal) and protracted (21 days after ethanol removal) ethanol-withdrawn rats, respectively. Acute and repeated topiramate treatment induced anxiolytic-like effects in naive rats. Early ethanol withdrawal increased anxiety, and acute topiramate administration counteracted the anxiogenic-like effects of ethanol removal. Protracted withdrawal did not produce lasting changes in anxiety but topiramate was equally effective at reducing anxiety in ethanol-withdrawn and control animals. Importantly, no signs of tolerance to the anxiolytic effects of topiramate were observed. In conclusion, these data support a role for topiramate in the treatment of basal levels of anxiety and ethanol withdrawal-induced anxiety. (PsycINFO Database Record

Effects of amantadine and topiramate on neuronal damage in rats with experimental cerebral ischemia-reperfusion

“…17 The dose range of topiramate reported in previous experimental studies is broad and often depends on the method of administration. For example, the efficacy of topiramate at a dose of 40-160 mg/kg/day in an inflammatory hyperalgesia model in rats 18 was demonstrated, and at a dose of 40 mg/kg/day 19 in studies on behavioral symptoms in rats. It has also been reported that hippocampal ischemic neuronal damage almost eliminates all histological findings.…”

Nukleus akumbens bölgesine uygulanan topiramatın morfin yoksunluk sendromu üzerine etkileri

“…Systemically administration of topiramate has been previously tested in alcohol withdrawal in experimental animals and has been shown to suppress withdrawal symptoms 23 . Topiramate treatment also exhibits anxiolytic effect in both early and late periods of alcohol withdrawal 39 . Few studies have examined the effects of topiramate on morphine withdrawal.…”

The efficacy of topiramate in alcohol dependence therapy – current research and prospects of use

“…Topiramate reduced the anxiety and hyperactivity that developed in the course of alcohol withdrawal syndrome both in the earlier and later abstinence periods. Furthermore, there was no observed development of tolerance to the anxiolytic activity of topiramate [49].…”

“…Wykazano skuteczność topiramatu w zmniejszaniu niepokoju i nadpobudliwości w przebiegu alkoholowego zespołu abstynencyjnego -zarówno we wczesnym, jak i późniejszym okresie abstynencji. Co istotne, nie zaobserwowano rozwoju tolerancji na anksjolityczne działanie topiramatu [49].…”